Focused Wealth Management Inc Has $3.24 Million Stock Holdings in Pfizer Inc. $PFE

Focused Wealth Management Inc cut its position in shares of Pfizer Inc. (NYSE:PFE) by 27.4% during the first quarter, HoldingsChannel.com reports. The firm owned 115,258 shares of the biopharmaceutical company’s stock after selling 43,459 shares during the period. Focused Wealth Management Inc’s holdings in Pfizer were worth $3,236,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Abound Financial LLC acquired a new position in Pfizer in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PFE. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Tuesday. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.75 on Wednesday. The stock has a market capitalization of $141.06 billion, a price-to-earnings ratio of 18.89 and a beta of 0.34. The firm’s 50-day moving average price is $26.13 and its two-hundred day moving average price is $26.33. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is presently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is getting credit for longer-term growth optionality in obesity and broader healthcare innovation, with some commentary highlighting its pipeline as an underappreciated driver and its use of AI to improve operations. Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Positive Sentiment: Several articles point to Pfizer’s dividend yield and its obesity pipeline as reasons some investors remain interested in the stock while waiting for new products to ramp. Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
• Neutral Sentiment: Pfizer said it will host a webcast of its August 4 second-quarter 2026 results call, which is a routine investor update rather than a direct catalyst. Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• Neutral Sentiment: Nike named Pfizer finance executive David Denton as its next CFO, which reflects positively on Pfizer’s leadership bench but is not a direct operating update for PFE shares. Nike Names Pfizer’s Denton as Next CFO
• Negative Sentiment: Pfizer’s experimental lung cancer drug sigvotatug vedotin failed to meet the main overall-survival goal in a late-stage trial versus chemotherapy, a setback that is weighing on sentiment around the stock today. Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: While the drug showed benefit in some subgroups, the mixed readout underscores ongoing execution risk in Pfizer’s oncology portfolio, especially for assets tied to its Seagen acquisition. Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.